- Home
- LBRDP vs ZLAB Comparison
LBRDP vs ZLAB Comparison
Compare LBRDP & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRDP | ZLAB |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | China |
| Employees | 1900 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | LBRDP | ZLAB |
|---|---|---|
| Price | $24.61 | $18.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $57.22 |
| AVG Volume (30 Days) | N/A | ★ 841.3K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $441,629,000.00 |
| Revenue This Year | N/A | $26.16 |
| Revenue Next Year | N/A | $30.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | N/A | $16.82 |
| 52 Week High | N/A | $44.34 |
Technical Indicators
Market Signals| Indicator | LBRDP | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 40.35 |
| Support Level | $24.50 | $17.37 |
| Resistance Level | $24.73 | $19.01 |
| Average True Range (ATR) | 0.17 | 0.63 |
| MACD | 0.02 | 0.31 |
| Stochastic Oscillator | 68.89 | 57.51 |
Price Performance
Historical ComparisonAbout LBRDP Liberty Broadband Corporation Series A Cumulative Redeemable Preferred Stock
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.